Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
Eli Lilly & Co. is pouring $4.5 billion into a new manufacturing plant in Indiana to make drugs for future clinical trials, ...
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and ...
Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...
Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...
Lilly VandenBosch is in the process of becoming a nurse practitioner after living through a childhood battling the rare blood ...
From Mirror staff reports An 18-year-old Lilly man was killed in a crash Thursday morning in Cambria County. Cambria County Coroner Jeff Lees said David Swinger died instantly from massive chest ...
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback